Botulinum poison (Botox) is a neurotoxic protein created by the bacterium Clostridium botulinum and related species. It forestalls the arrival of the synapse acetylcholine from axon endings at the neuromuscular intersection and accordingly causes flabby paralysis. Infection with the bacterium causes the ailment botulism. The poison is likewise utilized industrially for clinical and restorative purposes.
There are seven principle kinds of botulinum poison, named type A–G. New sorts are every so often found. Types An and B are equipped for causing infection in people, and are likewise utilized monetarily and medically. Types C–G are less normal; types E and F can cause malady in people, while different sorts cause sickness in other animals. Botulinum poison types An and B are utilized in medication to treat different muscle fits.
Botulinum poison is the most harmful substance known. Inebriation can happen normally because of either twisted or intestinal disease or by ingesting preformed poison in food. The assessed human deadly portion of type A poison is 1.3–2.1 ng/kg intravenously or intramuscularly, 10–13 ng/kg when breathed in, or 1000 ng/kg when taken by mouth. Commercial structures are advertised under the brand names Botox (onabotulinumtoxinA), Dysport/Azzalure (abobotulinumtoxinA), Xeomin/Bocouture (incobotulinumtoxinA),and Jeuveau (prabotulinumtoxinA).
Mini Review: Medical & Clinical Reviews
Mini Review: Medical & Clinical Reviews
Research Article: Medical & Clinical Reviews
Research Article: Medical & Clinical Reviews
Commentary: Medical & Clinical Reviews
Commentary: Medical & Clinical Reviews
Review Article: Medical & Clinical Reviews
Review Article: Medical & Clinical Reviews
Review Article: Medical & Clinical Reviews
Review Article: Medical & Clinical Reviews
Posters & Accepted Abstracts: Journal of Universal Surgery
Posters & Accepted Abstracts: Journal of Universal Surgery
Posters & Accepted Abstracts: Chronic Obstructive Pulmonary Disease: Open Access
Posters & Accepted Abstracts: Chronic Obstructive Pulmonary Disease: Open Access
Medical & Clinical Reviews received 906 citations as per Google Scholar report